ABEO
ABEO
Positions held
Your positionsABEO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-22 · Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
2026-09-22 · Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
2026-09-17 · ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
2026-09-16 · Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
2026-09-16 · Abeona Therapeutics Activates 8th ZEVASKYN Treatment Center in Florida
2026-09-02 · Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
2026-09-01 · Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-21 · Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
2026-08-17 · Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
Price (daily)
Full chart · RSI · MACD · patterns